Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Malignant Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Malignant Neoplasm
Secondary Malignant Neoplasm

Cancer Family

Secondary Malignant Neoplasm

CI-CAN-00000346SMNExplore in graph →

4,275 active trials56 approved drugs532 evidence items

NCIt: C4968

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14671
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.
· Clin Cancer Res · 2009 · PMID 19584151 · validated civic_curation pubmed
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.
· Clin Cancer Res · 2012 · PMID 22090360 · validated civic_curation pubmed
p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma.
· J Natl Cancer Inst · 1996 · PMID 8901856 · validated civic_curation pubmed
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.
· J Cell Mol Med · 2009 · PMID 19040416 · validated civic_curation pubmed
FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.
· Virchows Arch · 2014 · PMID 25086725 · validated civic_curation pubmed
Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.
· Ann Oncol · 2014 · PMID 24577117 · validated civic_curation pubmed
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
· Lancet Oncol · 2013 · PMID 23746666

Showing 101–125 of 486 publications

← Previous
1
…
4
5
6
…
20
Next →

· validated civic_curation

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.

· PLoS One · 2015 · PMID 26313362 · validated civic_curation pubmed

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

· Oncotarget · 2016 · PMID 26625204 · validated civic_curation pubmed

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

· J Clin Oncol · 2010 · PMID 20142587 · validated civic_curation pubmed

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

· J Natl Cancer Inst · 1998 · PMID 9625170 · validated civic_curation pubmed

The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.

· Clin Transl Oncol · 2016 · PMID 26459251 · validated civic_curation pubmed

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

· J Clin Oncol · 2013 · PMID 23213094 · validated civic_curation pubmed

p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.

· J Clin Oncol · 2014 · PMID 25267748 · validated civic_curation pubmed

Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib.

· Onco Targets Ther · 2015 · PMID 26309414 · validated civic_curation pubmed

Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.

· Clin Cancer Res · 2011 · PMID 21653686 · validated civic_curation pubmed

Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.

· PLoS One · 2014 · PMID 24740294 · validated civic_curation pubmed

A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

· Ann Oncol · 2014 · PMID 25081901 · validated civic_curation pubmed

Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.

· Anticancer Res · 2013 · PMID 23645741 · validated civic_curation pubmed

DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.

· Eur J Cancer · 2011 · PMID 21458988 · validated civic_curation pubmed

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

· Breast Cancer Res Treat · 2012 · PMID 22418700 · validated civic_curation pubmed

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

· Lancet Oncol · 2015 · PMID 26596672 · validated civic_curation pubmed

Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.

· Clin Cancer Res · 2015 · PMID 25370464 · validated civic_curation pubmed

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

· J Clin Oncol · 2014 · PMID 24868024 · validated civic_curation pubmed

High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.

· Mol Clin Oncol · 2016 · PMID 26893853 · validated civic_curation pubmed